Failure To Comply With BPCIA Mandates Precludes A Declaratory Judgment Suit

Dec 2, 2014

Reading Time : 1 min

In a slip opinion, the Southern District of New York Court recognized that the BPCIA statutory framework governs the dispute resolution process for disputes relating to the manufacture and marketing of biosimilar products (e.g., biologic drugs which are “highly similar” to an already FDA approved “reference product”). While a reference product enjoys exclusivity for a period of twelve years, the BPCIA provides for a relatively quick and inexpensive methodology for biosimilar manufacturers to gain FDA approval for their drugs which have ‘“no clinically meaningful differences’” from the reference product. The BPCIA includes a dispute resolution mechanism that is designed to ensure that patent disputes are resolved before the reference product’s exclusivity period terminates. The dispute resolution process mandated by the BPCIA includes the exchange of information and various notices to the parties. The court noted that, even had it not already found that the matter involved no actual case or controversy, the failure to adhere to the dispute resolution process set forth in the BPCIA will preclude the manufacturer of a biosimilar product from seeking a declaratory judgment of patent invalidity against a reference product sponsor.

Celltrion Healthcare Co., Ltd. V. Kennedy Trust for Rheumatology Research, 2014 WL 6765996 (S.D.N.Y. Dec. 1, 2014).

Share This Insight

Categories

Previous Entries

IP Newsflash

December 3, 2025

The Federal Circuit recently held that a patentee acted as its own lexicographer to define a claim term even though it did not explicitly define the term. Rather, because the patentee consistently and clearly used two terms interchangeably to describe the same structural feature and did so in all of the embodiments in which the feature appeared, the patentee impliedly gave the term its own, unique definition.

...

Read More

IP Newsflash

December 2, 2025

The Federal Circuit recently held an asserted patent was not entitled to its priority date because the priority application lacked written description support for the asserted claims. In so doing, the court explained that broad disclosures that do not provide reasonably specific support for narrower claims do not meet the written description requirement. The court also considered whether the inventor’s testimony showed they possessed the full scope of the claimed genus at the priority date or whether it was more likely the inventors first became aware of the claimed embodiments from public disclosures of the accused product.

...

Read More

IP Newsflash

December 1, 2025

In a Hatch-Waxman case, the District of Delaware denied a motion for summary judgment seeking to apply the ANDA filing date as the date of the hypothetical negotiation used to calculate reasonable royalty damages. Instead, the court determined that the appropriate date to use for the hypothetical negotiation is the launch date.

...

Read More

IP Newsflash

November 17,2025

The district of Delaware recently denied a defendant’s partial motion to dismiss pre-suit willful infringement from the litigation, finding instead that the allegations taken as a whole were sufficient to support pre-suit willfulness at the pleading stage. Specifically, the court found that the allegations as to the defendant’s involvement in a related foreign opposition proceeding and participation in the relevant industry were accompanied by detailed factual support that sufficiently pleaded willful infringement for the pre-suit period.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.